Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas

M. Merli, M. Frigeni, L. Alric, C. Visco, C. Besson, L. Mannelli, A. Di Rocco, A. Ferrari, L. Farina, M. Pirisi, F. Piazza, V. Loustaud-Ratti, A. Arcari, D. Marino, A. Sica, M. Goldaniga, C. Rusconi, M. Gentile, E. Cencini, F. BenantiM.G. Rumi, V.V. Ferretti, P. Grossi, M. Gotti, R. Sciarra, M.C. Tisi, I. Cano, V. Zuccaro, F. Passamonti, L. Arcaini

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)e720-e729
JournalOncologist
Volume24
Issue number8
DOIs
Publication statusPublished - 2019

Keywords

  • Diffuse large B-cell lymphoma
  • Direct-acting antivirals
  • Hepatitis C virus
  • R-CHOP
  • antivirus agent
  • cyclophosphamide
  • dasabuvir
  • doxorubicin
  • ledipasvir
  • paritaprevir
  • prednisone
  • ribavirin
  • ritonavir
  • rituximab
  • sofosbuvir
  • vincristine
  • adult
  • Article
  • chronic hepatitis
  • clinical article
  • clinical outcome
  • cohort analysis
  • diffuse large B cell lymphoma
  • drug tolerance
  • female
  • follow up
  • genotype
  • hepatitis C
  • human
  • liver toxicity
  • male
  • middle aged
  • multicenter study
  • overall survival
  • priority journal
  • progression free survival
  • retrospective study
  • sustained virologic response
  • treatment response

Cite this